Let the money flow like the Mississippi River
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Read properly brother!! Did you go to school
Let’s all hold hand and pray brothers and sisters go 10$ News
Who is making this high tech machine brother
Let’s all hold hands and pray for hail mary news
All eyes on FOXO
May god bless us all, Let’s all hold hands and pray fo a dolla
Let’s all hold hands and pray for the next Nvidia in healthcare epigenetics
Let’s all hold hands and pray for FOXO RNVA Merger success
https://www.investing.com/news/company-news/foxo-technologies-strikes-deals-adjusts-leadership-and-compensation-93CH-3547133
Long live FOXO God Bless
FOXO Technologies strikes deals, adjusts leadership and compensation
Investing.com
Editor
Lina Guerrero
Published 07/31/2024, 04:36 PM
FOXO Technologies strikes deals, adjusts leadership and compensation
In a series of strategic moves, FOXO Technologies Inc. (NYSE American:FOXO) has entered into multiple agreements and made key changes to its executive compensation, according to a recent 8-K filing with the Securities and Exchange Commission. These developments unfolded on July 25, 2024, marking a significant shift in the company's advisory and management structure.
FOXO, a Delaware-based company specializing in commercial physical and biological research, signed a Corporate Development Advisory Agreement with C L Talent Inc. The agreement, which commenced on July 17, 2024, will leverage the consultant's expertise in health, wellness, and social media to advise FOXO on business opportunities and talent engagement for a 12-month term. In exchange for these services, FOXO is set to issue 1.5 million shares of Class A Common Stock, pending approval from the New York Stock Exchange American.
Furthermore, the company has engaged J.H. Darbie & Co., Inc. as a nonexclusive financial adviser through an Advisory Agreement and for exclusive services related to private placements. J.H. Darbie will receive 625,000 shares of Class A Common Stock as compensation for its advisory role and will have a right of first refusal for any company financing for six months post-engagement. Additionally, J.H. Darbie will be compensated with a nonrefundable fee of $30,000 in Class A Common Stock and a potential maximum fee of 2% for its services in private placements.
In executive compensation news, FOXO has superseded an interim employment agreement with a new Services Agreement with Mark White, which extends until July 31, 2026. White will receive monthly fees of $30,000, with an option to convert into equity, and will be reimbursed for business expenses and vehicle leasing costs. He will also be issued 2,000 shares of Series A Preferred Stock. The agreement outlines severance terms, including 24 months of monthly fees and expense reimbursements, should White's service be terminated without cause or upon a change of control.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads.
InvestingPro Insights
As FOXO Technologies Inc. (NYSE American:FOXO) navigates through its strategic partnerships and executive compensation plans, it's important for investors to consider the financial landscape of the company. According to InvestingPro data, FOXO's market capitalization stands at a modest $2.68 million, reflecting the size and scale of its operations within the commercial physical and biological research sector. The company's revenue for the last twelve months as of Q1 2024 was reported at $0.14 million, which indicates a steep decline of 71.28% from the previous period. This contraction is mirrored in the company's gross profit margin, which is currently at 5.04%.
InvestingPro Tips highlight the stock's high volatility and its significant price decline over the past year, with a 1-year price total return of -89.84%. Additionally, the short-term obligations of FOXO exceed its liquid assets, which could signal potential liquidity risks. These financial metrics and stock performance indicators are essential for investors to consider when evaluating the company's future prospects, especially in light of the recent executive and advisory agreements.
For those looking to delve deeper into FOXO's financial health and stock performance, there are more InvestingPro Tips available, providing a comprehensive analysis of the company's market position and potential investment risks or opportunities. For additional insights and metrics, visit https://www.investing.com/pro/FOXO.
Praise the lord
FOXO Technologies strikes deals, adjusts leadership and compensation
Investing.com
Editor
Lina Guerrero
Published 07/31/2024, 04:36 PM
FOXO Technologies strikes deals, adjusts leadership and compensation
In a series of strategic moves, FOXO Technologies Inc. (NYSE American:FOXO) has entered into multiple agreements and made key changes to its executive compensation, according to a recent 8-K filing with the Securities and Exchange Commission. These developments unfolded on July 25, 2024, marking a significant shift in the company's advisory and management structure.
FOXO, a Delaware-based company specializing in commercial physical and biological research, signed a Corporate Development Advisory Agreement with C L Talent Inc. The agreement, which commenced on July 17, 2024, will leverage the consultant's expertise in health, wellness, and social media to advise FOXO on business opportunities and talent engagement for a 12-month term. In exchange for these services, FOXO is set to issue 1.5 million shares of Class A Common Stock, pending approval from the New York Stock Exchange American.
Furthermore, the company has engaged J.H. Darbie & Co., Inc. as a nonexclusive financial adviser through an Advisory Agreement and for exclusive services related to private placements. J.H. Darbie will receive 625,000 shares of Class A Common Stock as compensation for its advisory role and will have a right of first refusal for any company financing for six months post-engagement. Additionally, J.H. Darbie will be compensated with a nonrefundable fee of $30,000 in Class A Common Stock and a potential maximum fee of 2% for its services in private placements.
In executive compensation news, FOXO has superseded an interim employment agreement with a new Services Agreement with Mark White, which extends until July 31, 2026. White will receive monthly fees of $30,000, with an option to convert into equity, and will be reimbursed for business expenses and vehicle leasing costs. He will also be issued 2,000 shares of Series A Preferred Stock. The agreement outlines severance terms, including 24 months of monthly fees and expense reimbursements, should White's service be terminated without cause or upon a change of control.
As FOXO Technologies Inc. (NYSE American:FOXO) navigates through its strategic partnerships and executive compensation plans, it's important for investors to consider the financial landscape of the company. According to InvestingPro data, FOXO's market capitalization stands at a modest $2.68 million, reflecting the size and scale of its operations within the commercial physical and biological research sector. The company's revenue for the last twelve months as of Q1 2024 was reported at $0.14 million, which indicates a steep decline of 71.28% from the previous period. This contraction is mirrored in the company's gross profit margin, which is currently at 5.04%.
InvestingPro Tips highlight the stock's high volatility and its significant price decline over the past year, with a 1-year price total return of -89.84%. Additionally, the short-term obligations of FOXO exceed its liquid assets, which could signal potential liquidity risks. These financial metrics and stock performance indicators are essential for investors to consider when evaluating the company's future prospects, especially in light of the recent executive and advisory agreements.
For those looking to delve deeper into FOXO's financial health and stock performance, there are more InvestingPro Tips available, providing a comprehensive analysis of the company's market position and potential investment risks or opportunities. For additional insights and metrics, visit https://www.investing.com/pro/FOXO.
God bless all FOXO longs
Compliance news just hit brothers https://www.sec.gov/edgar/browse/?CIK=1812360&owner=exclude
Compliance news has arrived god bless FOXO
https://www.sec.gov/edgar/browse/?CIK=1812360&owner=exclude
Our prayers have been answered news has arrived
https://www.tipranks.com/news/company-announcements/foxo-technologies-bolsters-expertise-and-leadership-team
It can happen anytime brother, Explosive move as we all pray alleluia praise the lord
Every prayer will be answered as we sing alleluia to the lord
Everyone is praying for news brother… God is great
All praying for news.. May FOXO Save us all
It’s breakthrough status for all bagholders
I will pray till news comes out all day all night brothers
Hold my hand brother, and pray for News all day long…
Gearing up fo the dolla
It’s the last call all aboard the mississippi train brother… Don’t cry should would could when it’s in your face… Hold my hand and pray all day for FOXO
Hold my hand and pray my son… FOXO is the only thing here that can save you,
Hard work and dedication on the Ai line
Let’s all hold hands and sing alleluia to the lord
It’s the other way around brother…. but anyway hold my hands and pray for news
Hell yes.. Positive News can seriously move this sleeping giant
The pressure is building up for .30
It’s under the pressure cooker
Got a heart beat
Let’s all pray for FOXO News
Let’s all pray for compliance news
.30 to start the engines
Need the green algorithm
It’s in a coma!!
Hold my hands and pray brother
It was a flop!!
TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138
May 29 2024 - 9:15AM
Share On Facebook
TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced new preliminary data from its Phase 0 clinical trial with radiolabeled TTX-MC138 suggesting anti-tumor activity.
New results from the patient dosed in this trial indicate that a microdose of radiolabeled TTX-MC138 resulted in significant inhibition of the drug candidate’s molecular target, miRNA-10b, in the patient’s blood. Specifically, after injection, the amount of miR-10b in the patient’s blood was significantly reduced compared to levels prior to administration of radiolabeled TTX-MC138, reaching a reduction of 66% at 24 hours following dosing. “We believe these data are important given that in several animal models, miRNA-10b inhibition by TTX-MC138 resulted in complete regressions of metastatic disease,” stated Zdravka Medarova, PhD, Chief Scientific Officer at TransCode. These data support TransCode’s belief that clinical development of TTX-MC138 has the potential for clinical benefit in patients with metastatic cancer.
In addition, the study also quantified the amount of drug candidate delivered to metastatic lesions, providing further evidence that TTX-MC138 accumulated in metastatic tumors. The increase of radioactive lesion-to-blood ratios suggests that circulating TTX-MC138 is actively taken up by the cancerous tissue.
The microdose of radiolabeled TTX-MC138 was well tolerated with no adverse events observed.
“These new data suggest that TTX-MC138 not only inhibits the miRNA-10b target but is pharmacodynamically active at a single microdose in the patient’s serum, supporting continued clinical development of TTX-MC138 for the treatment of multiple metastatic cancers in the planned Phase 1 clinical study. This could indicate a much broader therapeutic window than had previously been expected,” said Dr. Daniel Vlock, TransCode’s Chief Medical Officer.